lisocabtagene maraleucel
bms
['transform,(-transformi),(-transforme),(-transforma),(-transforms),(-transform1),(-transform 1),(-transform-1),(-transform2),(-transform 2),(-transform-2)', 'liso-cel']
dr. abramson: liso-cel 2nd line transform trial, primary analysis, 18mo efs 52%, better than soc, 66% of soc crossed over to lido-cel. #ash22 
Hem/Onc, BMT, CAR-T, Immunology, Math, Machine Learning, Python, R, SAS. Tweets are my personal views